Infliximab monitoring in Crohn's disease: a neural network approach for evaluating disease activity and immunogenicity.

ABSTRACT:

Background

The treatment for Crohn's disease (CD) has increasingly required the use of biological agents. Safe and affordable tests have led to the active implementation of therapeutic drug monitoring (TDM) in clinical practice, which, although not yet widely available across all health services, has been proven effective.

Objective

To analyze serum infliximab (IFX) and antidrug antibody (ADA) levels in CD patients, compare two tests, as well as construct a prediction of neural network using a combination of clinical, epidemiological, and laboratory variables.

Design

Cross-sectional observational study.

Method

A cross-sectional observational study was conducted on 75 CD patients in the maintenance phase of IFX treatment. The participants were allocated into two

SUBMITTER: Gomes LEM 

PROVIDER: S-EPMC11632880 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature